Literature DB >> 3620698

Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with a low concentration of ionized calcium.

M A Packham, R L Kinlough-Rathbone, J F Mustard.   

Abstract

Close platelet-to-platelet contact induced by weak agonists in a medium with a low concentration of Ca2+ leads to thromboxane A2 (TXA2) formation, release of granule contents, and secondary aggregation. These responses do not occur in a medium containing Ca2+ in the physiological range (1 to 2 mmol/L). Experiments were done to determine whether feedback amplification is required to generate amounts of TXA2 that are sufficient to cause secondary aggregation and the reactions associated with it, or whether close platelet-to-platelet contact alone is sufficient to generate enough TXA2 to produce these responses. Platelets were washed and resuspended in a modified Tyrode solution to which no calcium salt was added that contained 0.35% albumin and apyrase. This medium contains 20 mumol/L Ca2+ and 1 mmol/L Mg2+. Platelets were aggregated with adenosine diphosphate (ADP) in the presence of fibrinogen, agglutinated with polylysine, or after pretreatment with chymotrypsin, aggregated with fibrinogen. In the low-Ca2+ medium, all these agonists caused platelets to adhere to each other, followed by secondary aggregation with TXA2 formation and release of granule contents. When Ca2+ (1 to 2 mmol/L), aspirin, or the thromboxane receptor blocker BM 13.177 was present, the secondary responses did not occur; dazoxiben decreased thromboxane formation, but did not prevent secondary aggregation or release. Aspirin-treated platelets were less responsive to ADP, U46619, or TXA2 in the low-Ca2+ medium, which indicated that the secondary responses of untreated platelets were not caused by a generalized increase in sensitivity. The reactions that result from close platelet-to-platelet contact in a low-Ca2+ medium can be caused by a wide variety of weak agonists; the secondary aggregation response and release of granule contents are dependent on TXA2 formation and on feedback amplification by TXA2 or the prostaglandin endoperoxides. The secondary responses caused by weak agonists in citrated platelet-rich plasma (which has a concentration of Ca2+ similar to the low-Ca2+ medium used in the present studies) do not occur at the concentration of Ca2+ in circulating blood and thus may have little biologic relevance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3620698

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor.

Authors:  Yingying Mao; Lili Zhang; Jianguo Jin; Barrie Ashby; Satya P Kunapuli
Journal:  Eur J Pharmacol       Date:  2010-06-30       Impact factor: 4.432

2.  Pharmacological characteristics of solid-phase von Willebrand factor in human platelets.

Authors:  A Radomski; M W Stewart; P Jurasz; M W Radomski
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

3.  Autocrine amplification of integrin αIIbβ3 activation and platelet adhesive responses by deoxyribose-1-phosphate.

Authors:  Dina S Vara; Michelangelo Campanella; Ilaria Canobbio; Warwick B Dunn; Giuseppe Pizzorno; Michio Hirano; Giordano Pula
Journal:  Thromb Haemost       Date:  2013-03-14       Impact factor: 5.249

4.  Effects of trimetazidine on in vivo coronary arterial platelet thrombosis.

Authors:  P R Belcher; A J Drake-Holland; J W Hynd; M I Noble
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

5.  Characterization of a new peptide agonist of the protease-activated receptor-1.

Authors:  Yingying Mao; Jianguo Jin; Satya P Kunapuli
Journal:  Biochem Pharmacol       Date:  2007-09-08       Impact factor: 5.858

6.  Extracellular Ca(2+) modulates ADP-evoked aggregation through altered agonist degradation: implications for conditions used to study P2Y receptor activation.

Authors:  Sarah Jones; Richard J Evans; Martyn P Mahaut-Smith
Journal:  Br J Haematol       Date:  2011-02-20       Impact factor: 6.998

7.  Platelet function testing at low platelet counts: When can you trust your analysis?

Authors:  Niklas Boknäs; Ankit S Macwan; Anna L Södergren; Sofia Ramström
Journal:  Res Pract Thromb Haemost       Date:  2019-03-19

8.  Platelets from platelet-rich-plasma versus buffy-coat-derived platelets: what is the difference?

Authors:  Hans Gulliksson
Journal:  Rev Bras Hematol Hemoter       Date:  2012
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.